Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 4,449,863 shares, a decrease of 22.2% from the November 15th total of 5,717,770 shares. Approximately 20.3% of the shares of the stock are short sold. Based on an average trading volume of 1,238,901 shares, the short-interest ratio is presently 3.6 days.

In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total value of $79,367.25. Following the sale, the insider now directly owns 28,513 shares in the company, valued at $491,849.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the company’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $17.34, for a total value of $17,340,000.00. The disclosure for this sale can be found here. Insiders sold 1,058,630 shares of company stock worth $18,264,360 over the last quarter. Company insiders own 25.76% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Voya Investment Management LLC bought a new position in Collegium Pharmaceutical in the second quarter valued at about $125,000. Nationwide Fund Advisors boosted its holdings in Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after acquiring an additional 2,802 shares during the last quarter. Credit Suisse AG boosted its holdings in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after acquiring an additional 1,173 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Collegium Pharmaceutical in the second quarter valued at about $198,000. Finally, State of Wisconsin Investment Board bought a new position in Collegium Pharmaceutical in the second quarter valued at about $225,000. Institutional investors and hedge funds own 79.98% of the company’s stock.

COLL has been the topic of several research analyst reports. HC Wainwright initiated coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They set a “buy” rating and a $21.00 target price on the stock. Jefferies Group restated a “buy” rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, September 21st. Needham & Company LLC restated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Monday, November 13th. Finally, Piper Jaffray Companies set a $19.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $23.50.

Shares of Collegium Pharmaceutical (COLL) opened at $17.30 on Friday. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business’s revenue for the quarter was up 2814.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.13) earnings per share. equities research analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current year.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/12/15/collegium-pharmaceutical-inc-coll-short-interest-update.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.